Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 11180

1.

ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.

Triviai I, Zeschke S, Rentel J, Spanakis M, Scherer T, Gabdoulline R, Panagiota V, Thol F, Heuser M, Stocking C, Kröger N.

Leukemia. 2018 Jun 15. doi: 10.1038/s41375-018-0159-0. [Epub ahead of print]

PMID:
29907810
2.

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.

Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, Afanasyev B, Ciceri F, Mohty M, Nagler A.

Leukemia. 2018 Jun 15. doi: 10.1038/s41375-018-0170-5. [Epub ahead of print]

PMID:
29907809
3.

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.

Ernst T, Busch M, Rinke J, Ernst J, Haferlach C, Beck JF, Hochhaus A, Gruhn B.

Leukemia. 2018 Jun 13. doi: 10.1038/s41375-018-0157-2. [Epub ahead of print] No abstract available.

PMID:
29899367
4.

Multiple myeloma clonal evolution in homogeneously treated patients.

Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, Munshi N, Avet-Loiseau H.

Leukemia. 2018 Jun 12. doi: 10.1038/s41375-018-0153-6. [Epub ahead of print]

PMID:
29895955
5.

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U.

Leukemia. 2018 Mar 30. doi: 10.1038/s41375-018-0118-9. [Epub ahead of print]

PMID:
29895954
6.

Correction: A human bone marrow mesodermal-derived cell population with hemogenic potential.

Mokhtari S, Colletti E, Yin W, Sanada C, Lamar Z, Simmons PJ, Walker S, Bishop C, Atala A, Zanjani ED, Porada CD, Almeida-Porada G.

Leukemia. 2018 Jun 11. doi: 10.1038/s41375-018-0172-3. [Epub ahead of print]

PMID:
29891936
7.

Response kinetics and factors predicting survival in core-binding factor leukemia.

Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0158-1. [Epub ahead of print] No abstract available.

PMID:
29884905
8.

Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.

Boudreaux SP, Duren RP, Call SG, Nguyen L, Freire PR, Narayanan P, Redell MS, Conneely OM.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0174-1. [Epub ahead of print]

PMID:
29884904
9.

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.

Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0169-y. [Epub ahead of print]

PMID:
29884903
10.

Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.

Timilshina N, Breunis H, Tomlinson GA, Brandwein JM, Buckstein R, Durbano S, Alibhai SMH.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0162-5. [Epub ahead of print]

PMID:
29884902
11.

Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.

Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, Zarabi SF, Gronda M, Hurren R, Jeyaraju DV, MacLean N, Brennan S, Hyer ML, Berger A, Traore T, Milhollen M, Smith AC, Minden MD, Pai EF, Hakem R, Schimmer AD.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0167-0. [Epub ahead of print]

PMID:
29884901
12.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Apr 25. doi: 10.1038/s41375-018-0142-9. [Epub ahead of print] Review.

PMID:
29880892
13.

New drugs in AML: uses and abuses.

Estey EH, Gale RP, Sekeres MA.

Leukemia. 2018 Jun 6. doi: 10.1038/s41375-018-0168-z. [Epub ahead of print] No abstract available.

PMID:
29875431
14.

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Burnett AK, Hills RK, Nielsen OJ, Freeman S, Ali A, Cahalin P, Hunter A, Thomas IF, Russell NH.

Leukemia. 2018 Jun 6. doi: 10.1038/s41375-018-0148-3. [Epub ahead of print] No abstract available.

PMID:
29875430
15.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.

Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD.

Leukemia. 2018 Jun 5. doi: 10.1038/s41375-018-0147-4. [Epub ahead of print]

PMID:
29872168
16.

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.

Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, Song Y, Vasic R, Maziarz J, Balasubramanian K, Ardasheva A, Ding A, Quattrone A, Halene S.

Leukemia. 2018 Jun 1. doi: 10.1038/s41375-018-0152-7. [Epub ahead of print]

PMID:
29858584
17.

Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.

Lakshman A, Ravi P, Rajkumar SV, Kumar SK.

Leukemia. 2018 May 25. doi: 10.1038/s41375-018-0155-4. [Epub ahead of print] No abstract available.

PMID:
29802327
18.

Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014.

Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez A, van den Heuvel-Eibrink MM, Kremer LCM, Gilbert ES, van Leeuwen FE, Ronckers CM, Morton LM.

Leukemia. 2018 May 24. doi: 10.1038/s41375-018-0149-2. [Epub ahead of print]

PMID:
29795414
19.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 May 24. doi: 10.1038/s41375-018-0150-9. [Epub ahead of print]

PMID:
29795413
20.

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K.

Leukemia. 2018 May 23. doi: 10.1038/s41375-018-0154-5. [Epub ahead of print]

PMID:
29795241

Supplemental Content

Loading ...
Support Center